ArticleClinical neuroradiology2026
Impact of Heart Failure Phenotype on Functional Outcomes After Carotid Artery Stenting.
Article in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a common comorbidity in patients undergoing carotid artery stenting (CAS), but its impact on outcomes by HF phenotype is unclear. This is the first study to compare short-term CAS outcomes between patients with heart failure with reduced ejection fraction (HFrEF) and those with preserved ejection fraction (HFpEF).
methodsThis multicenter, prospective observational study started by screening 889 patients from the CASSH registry. After applying predefined criteria, 105 patients with heart failure undergoing CAS were included (69 HFpEF, 36 HFrEF). Baseline demographics, comorbidities, and procedural details were compared. The primary outcome was a composite of 30-day procedure-related mortality, stroke, or myocardial infarction. Secondary outcomes included disability, measured by the modified Rankin Scale (mRS), at 30 days and at 90 days. Multivariable ordinal regression was used to assess the independent association between HF phenotype and poor functional outcome.
resultsBaseline characteristics were similar between groups. The primary outcome occurred in 5.6% of HFrEF patients versus 1.4% of HFpEF patients (p = 0.561). However, functional outcomes were significantly worse in the HFrEF group, with higher mean mRS scores at 30 days (2.7 vs. 1.6, p = 0.003) and 90 days (2.7 vs. 1.4, p = 0.001). All-cause mortality was 11.1% in HFrEF vs. 1.4% in HFpEF (p = 0.085). After adjustment for age, sex, atrial fibrillation, and preprocedural mRS, HFrEF was independently associated with a higher risk of poor functional outcome at 30 days (β = 0.89, p = 0.018) and 90 days (β = 1.05, p = 0.006).
conclusionHFrEF, but not HFpEF, independently predicts poorer functional recovery following CAS. These findings highlight the importance of incorporating heart failure phenotype into risk stratification and clinical guidelines to improve patient selection and peri-procedural management.
Indexed as
Identifiers
42611061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.